MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BOYD, H.
Right arrow Articles by MARTIN, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BOYD, H.
Right arrow Articles by MARTIN, T. J.

Molecular Pharmacology, Vol 13, 576-578, Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics

The Effect of Propranolol on Induction of Rat Liver Tumors by a Chemical Carcinogen

HELEN BOYD 1 and T. J. MARTIN 1

1 Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria 3084, Australia

Previous work has indicated that during chemical carcinogenesis in rat liver there is an increase in the catecholamine responsiveness of adenylate cyclase. To investigate what role the increased beta adrenergic responsiveness of the enzyme might play in neoplastic transformation, the effect of the beta adrenergic blocker propranolol on tumor incidence in rat liver has been investigated during treatment with the carcinogen 3'-methyl-4-dimethylaminoazobenzene. Propranolol, administered in the drinking water during carcinogen treatment, approximately doubled tumor incidence. It is concluded that increased beta adrenergic responsiveness is unlikely to be a process causal to cancer and, moreover, that propranolol somehow facilitates neoplastic transformation in this systern. Whether such an effect of propranolol is due to specific beta blockade or to nonspecific actions remains to be elucidated.

Note:
ACKNOWLEDGMENTS We wish to express our gratitude to Karl Liebel for his help with these experiments, and to ICI for a gift of propranolol.

Submitted on October 1, 1976
Accepted on November 30, 1976




This article has been cited by other articles:


Home page
 Eur Heart JHome page
E Grossman, F.H Messerli, and U Goldbourt
Antihypertensive therapy and the risk of malignancies
Eur. Heart J., August 1, 2001; 22(15): 1343 - 1352.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics